Celyad VP On IP Issues, Development Timelines For CAR-T Therapies

26 Apr 2017

Georges Rawadi, vice president of business development and intellectual property at Celyad, talks to Scrip on the sidelines of the recent BIO-Europe Spring partnering conference in Barcelona about the company's pipeline of CAR-T therapies and recently resolved patent disputes for its technology.

Video interview — Celyad's George Rawadi talks to Scrip

Georges Rawadi, vice president of business development and intellectual property at Celyad SA, discusses the company's chimeric antigen receptors T- cells (CAR-T) pipeline, recently resolved IP issues and the firm's strategy for future clinical development.

On the sidelines of the recent BIO-Europe Spring partnering meeting, held in Barcelona, Mar. 20-22, Rawadi talks about how Celyad's technology will compete with other treatments coming through the immuno-oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

21 May 2025

• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.